BPC-157 Side Effects

Mild: continue protocol

Transient mild symptoms (slight GI upset, minor injection-site reaction, brief fatigue) typically resolve within 3-7 days as physiology adjusts. Continue at current dose; monitor weekly.

Moderate: reduce dose

Persistent mild symptoms past two weeks, or new symptoms like sustained mood changes, sleep disruption, or appetite shifts. Reduce dose by 25-50% and reassess at the end of the next 2-week window.

Severe: discontinue + seek care

Any signal of allergic response (rash, swelling, breathing difficulty), unexplained chest discomfort, severe injection-site reaction with infection signs, or vision changes. Discontinue immediately and consult a licensed practitioner.

What are the most common BPC-157 side effects?

Not established as well tolerated: a 2025 systematic review found no clinical safety data (PMID: 40756949), and FDA's 2026 review found three adverse event reports through 4 December 2025, all with injected BPC-157 (an injection-site reaction, shortness of breath, and skin and gum darkening with a product that also held TB-500), with causality unclear. No controlled trial has attributed any of the

Are there severe side effects to watch for with BPC-157?

Severe reactions are rare in published research but can occur. Watch for: allergic-type symptoms (rash, swelling, breathing difficulty), unexplained chest discomfort, infection signs at injection sites, vision changes, or severe persistent mood/sleep disruption. Any of these warrants immediate discontinuation and consultation with a licensed practitioner. The Severity Tiers section above triages mild → moderate → severe response patterns.

Does BPC-157 have contraindications?

Active cancer or history of cancer (due to angiogenic properties). Pregnancy or breastfeeding. Concurrent use of anticoagulants (may affect platelet function). Caution in patients with active infections where increased blood flow could spread pathogens.

How can I minimize BPC-157 side effects?

Three biggest levers: (1) Start at the Beginner-tier dose for 2-3 weeks before escalating, which gives time to detect adverse signals at minimum effective dose. (2) Source from COA-verified vendors only: impurity profiles and mislabeled compounds drive a disproportionate share of reported side effects in research-compound communities. (3) Maintain adequate cycle off-time when applicable: receptor-saturating compounds benefit from 4-6 week breaks. The vendor section below lists the cheapest in-stock BPC-157 sources we track, each linked to its Trust Score (COA verification is 30% of the score).